AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL SEVERANCE BENEFITS AGREEMENTControl Severance Benefits Agreement • May 18th, 2011 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
This Amended and Restated Executive Change in Control Severance Benefits Agreement (the “Agreement”) is entered into as of May 18, 2011 (the “Effective Date”), between Kaye Foster-Cheek (“Executive”) and Onyx Pharmaceuticals, Inc. (the “Company”) and amends and restates the prior Executive Change in Control Severance Benefits Agreement between the Company and Executive dated September 30, 2010 (the “Original Date”). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to a qualifying termination of employment in connection with a Change in Control. Certain capitalized terms used in this Agreement are defined in Article 5.
